Cancer Archive — Page 58 of 68
-
December 5, 2013
Predictor of prostate cancer outcomes identified
Researchers at Vanderbilt University Medical Center and the University of Alberta in Canada have identified a biomarker for a cellular switch that accurately predicts which prostate cancer patients are likely to have their cancer recur or spread. -
November 21, 2013
Therapeutic target for synovial sarcoma
Inhibitors of a signaling pathway that is critical to synovial sarcoma tumorigenesis may be useful treatments for this aggressive cancer. -
November 14, 2013
Family’s support enhances cancer research training
John F. Brock III, chairman and CEO of Coca-Cola Enterprises, his wife, Mary, and their three children have established an endowment to support an oncology fellowship at Vanderbilt-Ingram Cancer Center. The Brock Family Fellowship will provide financial assistance long into the future for young physicians, postdoctoral students and medical investigators who are furthering their training in cancer research. -
November 13, 2013
Molecular circuits in ovarian cancer
Vanderbilt researchers have used bioinformatics analysis of gene expression data to describe molecular “circuits” that drive ovarian cancer. -
November 7, 2013
VU study sheds new light on DNA replication
David Cortez, Ph.D., and his Vanderbilt colleagues report new findings that shed light on fundamental processes involved in DNA replication and have implications for cancer therapies that target these processes. -
October 17, 2013
New technique tracks breast cancer subtypes, treatment effectiveness
A group of Vanderbilt researchers has used laser technology and a custom-built multiphoton microscope to distinguish breast cancer subtypes and determine if specific therapies are working against the cancer cells in as little as two days. -
October 10, 2013
Probing mutant EGF receptor regulation
Understanding the regulation of mutant EGF receptors commonly found in lung cancers could lead to new targeted therapies.